Schlumberger R&D decreased by 12.3% to $164.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 4.7%, from $172.00M to $164.00M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 6.4% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $134.00M | $140.00M | $145.00M | $141.00M | $154.00M | $160.00M | $178.00M | $174.00M | $163.00M | $186.00M | $187.00M | $182.00M | $188.00M | $187.00M | $192.00M | $172.00M | $180.00M | $170.00M | $187.00M | $164.00M |
| QoQ Change | — | +4.5% | +3.6% | -2.8% | +9.2% | +3.9% | +11.3% | -2.2% | -6.3% | +14.1% | +0.5% | -2.7% | +3.3% | -0.5% | +2.7% | -10.4% | +4.7% | -5.6% | +10.0% | -12.3% |
| YoY Change | — | — | — | — | +14.9% | +14.3% | +22.8% | +23.4% | +5.8% | +16.3% | +5.1% | +4.6% | +15.3% | +0.5% | +2.7% | -5.5% | -4.3% | -9.1% | -2.6% | -4.7% |